|
|
 |
|
Viewing report
|
|
|
|
Assessment of the Molecular Diagnostic Market for Warfarin sensitivity (CYP2C9, VKOR1) NA Tests in UK
Data Information Intelligence GmbH, April 2009, Pages: 16
Hospital and private laboratories have been surveyed to collect information on NA tests performed, test volumes and used platforms and reagents. For data reliability and accurate projections at segment level a 3 step methodology has been applied:
Step 1: Identification of the total number of laboratories by secondary research and short telephone interviews with 561 hospitals to verify existence of internal laboratories.
Step 2: 355 laboratories in UK were classified for NAT activity and overall NA test volume.
Step 3: 36 laboratories provided data on NA test volume, kits, platforms and trends. A list of 44 NA tests have been provided to the labs for structured data entry. All data has been analysed and projected at total market level. Data is available by test and country.
Executive Summary
dii is an international marketing consulting company entirely specialised in healthcare markets providing market information and support to strategic market decisions. In cooperation with key industry a Continuous European Molecular Market Assessment has been realized in 2009 with the 2 main objectives:
1) Classification of laboratories by ownership, size and overall NA test volume
2) Market assessment for 44 NA tests on volumes, trends, kits and analyzers. All data is presented in Excel and PPT. Excel addresses all quantitative questions at segment level, including all volume projection scenarios and statistical detail, PPT presents the key data and provides an interpretation of general business implications
Customers who bought this item also bought
Assessment of the Molecular Diagnostic Market for 44 NA Tests in Spain
Assessment of the Molecular Diagnostic Market for 44 NA Tests in Germany
Assessment of the Molecular Diagnostic Market for 44 NA Tests in France
Assessment of the Molecular Diagnostic Market for 44 NA Tests in Italy
Assessment of the Molecular Diagnostic Market for 44 NA Tests in UK
Assessment of the Molecular Diagnostic Market for Factor V Leiden NA Tests in Italy
Assessment of the Molecular Diagnostic Market for Factor V Leiden NA Tests in France
Assessment of the Molecular Diagnostic Market for Cystic Fibrosis, Mucoviscoidosis NA Tests in Italy
Assessment of the Molecular Diagnostic Market for Her2Neu NA Tests in UK
Assessment of the Molecular Diagnostic Market for Cystic Fibrosis, Mucoviscoidosis NA Tests in UK
|
|
|
|
